Trump's Pharma Tariffs Threaten Industry Stability and Innovation

President Trump’s proposal to impose tariffs on pharmaceutical imports aims to address trade imbalances but risks disrupting the supply of essential medicines in the U.S., which heavily depends on China and India for raw materials. While bringing manufacturing back to the U.S. could enhance national security, the low margins and high costs make it challenging, and a comprehensive approach involving innovation, modernization, and large-scale initiatives is needed to reduce dependency and ensure drug supply stability.